Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04079140
Other study ID # vaginal dinoprostone IUD
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 15, 2019
Est. completion date December 10, 2019

Study information

Verified date July 2020
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To investigate whether vaginal dinoprostone administered before the levonorgestrel-releasing intrauterine system(IUs) insertion reduces IUD insertion pain and difficulty in insertion in adolescents and young women.


Description:

Long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that provides reliable, effective and long term contraception for many women. However, the insertion procedure can be associated with a troublesome degree of pain that prevent some women from choosing its use. Different interventions have been described to decrease pain perception during intrauterine device insertion with no agreement on an effective one.


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date December 10, 2019
Est. primary completion date November 30, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 22 Years
Eligibility Inclusion Criteria:

- nulliparous adolescent and young women requesting levonorgestrel-releasing intrauterine device

Exclusion Criteria:

- pregnancy and contraindication or allergy to dinoprostone or contraindication to IUD insertion, chronic pelvic pain,pelvic inflammatory disease,analgesic intake 24 hours prior to IUD insertion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dinoprostone
1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
placebo
one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.

Locations

Country Name City State
Egypt faculty of medicine Cairo university Giza

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference in pain scores during intrauterine device insertion The difference in pain scores during intrauterine device insertion using visual analog scale from 0 to 10 10 minutes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04301349 - Dinoprostone vs Misoprostol Before LNG-IUD Insertion Phase 3
Recruiting NCT06335823 - Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Reduction During Intrauterine Device (IUD) Insertion in Outpatient Gynecology N/A
Completed NCT03499743 - Celecoxib Versus Hyoscine Butyl-bromide in Reducing Pain Associated With IUD. N/A
Completed NCT04312048 - the Effect of Isosorbide Mononitrate in Reducing Pain During Cooper Intrauterine Device Insertion Phase 3